6955 Stock Overview
A development stage company, manufactures medical instruments and solutions for the male infertility market. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bonraybio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$140.50 |
| 52 Week High | NT$162.50 |
| 52 Week Low | NT$71.30 |
| Beta | 0 |
| 1 Month Change | 2.18% |
| 3 Month Change | 4.07% |
| 1 Year Change | 95.14% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 87.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6955 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 2.2% | 1.7% | 0.3% |
| 1Y | 95.1% | 2.1% | 27.4% |
Return vs Industry: 6955 exceeded the TW Biotechs industry which returned 2.1% over the past year.
Return vs Market: 6955 exceeded the TW Market which returned 27.4% over the past year.
Price Volatility
| 6955 volatility | |
|---|---|
| 6955 Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6955 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6955's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | bonraybio.com |
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also offers consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes.
Bonraybio Co., Ltd. Fundamentals Summary
| 6955 fundamental statistics | |
|---|---|
| Market cap | NT$2.77b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6955 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6955 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6955 perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 10:15 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bonraybio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|